ACE and type 2 diabetes mellitus: Considering that ACE inhibitors or ARBs are the first-line drugs for antihypertensive treatment in patients with type 2 diabetes (T2D) and have potential “nonclassical” RAS-mediated benefits, it is meaningful to measure the change in the plasma levels of “nonclassical” RAS components after drug treatment.